Related Experiment Videos
Cyclosporin A inhibits the growth of Cryptococcus neoformans in a murine model
C H Mody1, G B Toews, M F Lipscomb
1Department of Internal Medicine, University of Texas Health Science Center, Dallas 75235.
Abstract:
Cryptococcus neoformans is a frequent opportunistic infectious agent in patients with decreased T-lymphocyte-mediated immune function, including those with acquired immune deficiency syndrome. Cyclosporin A (CsA), a potent inhibitor of T-lymphocyte function, was administered subcutaneously to mice to study the pathogenesis of C. neoformans infections in the setting of impaired T-cell function. Surprisingly, survival was prolonged indefinitely in animals that received immunosuppressive doses of CsA following either intratracheal or intravenous inoculations of C. neoformans. Furthermore, following intratracheal inoculation, mice treated with CsA cleared C. neoformans from their lungs more rapidly than did control mice. CsA directly inhibited the growth of C. neoformans when it was added to cultures in vitro at concentrations comparable to the blood levels achieved in experimental mice. Thus, CsA inhibited both in vitro and in vivo growth of C. neoformans. While these results must be extended to studies in humans, these data suggest that patients who now receive CsA-immunosuppressive therapy may be fortuitously protected against infections with C. neoformans. Furthermore, research into cyclosporin derivatives may yield compounds with less immunosuppressive properties and enhanced antifungal activity.
Insights
Cyclosporin A (CsA) unexpectedly prolonged survival and enhanced clearance of Cryptococcus neoformans in mice. This immunosuppressive drug demonstrated direct antifungal activity, suggesting potential therapeutic benefits.
Area of Science:
- Mycology
- Immunology
- Pharmacology
Background:
- Cryptococcus neoformans is an opportunistic pathogen causing severe infections in immunocompromised individuals, particularly those with diminished T-lymphocyte function.
- Acquired immune deficiency syndrome (AIDS) is a primary condition associated with increased susceptibility to Cryptococcus neoformans infections.
Purpose of the Study:
- To investigate the effects of Cyclosporin A (CsA) on the pathogenesis of Cryptococcus neoformans infections in a mouse model with impaired T-cell function.
- To evaluate the direct antifungal activity of CsA against Cryptococcus neoformans in vitro and in vivo.
Main Methods:
- Administration of immunosuppressive doses of Cyclosporin A (CsA) subcutaneously to mice.
- Intratracheal and intravenous inoculation of Cryptococcus neoformans in mice.
- In vitro culture of Cryptococcus neoformans with varying concentrations of CsA.
- Monitoring of survival rates and fungal clearance from lungs in treated and control groups.
Main Results:
- Mice receiving immunosuppressive doses of CsA exhibited prolonged survival following Cryptococcus neoformans inoculation.
- CsA treatment led to more rapid clearance of Cryptococcus neoformans from the lungs in mice after intratracheal inoculation.
- Cyclosporin A demonstrated direct inhibition of Cryptococcus neoformans growth in vitro at concentrations achievable in vivo.
Conclusions:
- Cyclosporin A possesses both in vitro and in vivo antifungal activity against Cryptococcus neoformans.
- Current immunosuppressive therapy with CsA may offer incidental protection against Cryptococcus neoformans infections in patients.
- Further research into CsA derivatives could lead to novel antifungal agents with reduced immunosuppressive effects.